30/4/2025, 2:59:03 pm

Gland Pharma new drug appplication gets USFDA approval

Gland Pharma received USFDA approval for its abbreviated new drug application for latanoprostene bunod ophthalmic solution, 0.024%, a generic equivalent to Bausch and Lomb's VYZULTA. The drug treats open-angle glaucoma or ocular hypertension. Gland Pharma is the exclusive first-to-file and eligible for 180 days of generic drug exclusivity.